Vpositive-D(e1,e2)	The substitution of <e1> VARIANT </e1> (<e1> VARIANT </e1>) ablates the function of human galactose-1-phosphate uridyltransferase (GALT) and is the most common mutation causing <e2> DISEASE </e2> in the white population.
Vpositive-D(e1,e2)	Fluctuation analysis was used to characterize changes in the apparent double-gate behavior of the ClC-1 mutations <e1> VARIANT </e1> and VARIANT causing, respectively, a dominant and a recessive form of <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	Fluctuation analysis was used to characterize changes in the apparent double-gate behavior of the ClC-1 mutations VARIANT and <e1> VARIANT </e1> causing, respectively, a dominant and a recessive form of <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	<e1> VARIANT </e1> and VARIANT each account for around 20% of <e2> DISEASE </e2> alleles in the Dutch patient group, whilst VARIANT, VARIANT, VARIANT and VARIANT each have a frequency of about 6% in Australasian patients.
Vpatient-D(e1,e2)	VARIANT and <e1> VARIANT </e1> each account for around 20% of <e2> DISEASE </e2> alleles in the Dutch patient group, whilst <e1> VARIANT </e1>, VARIANT, VARIANT and VARIANT each have a frequency of about 6% in Australasian patients.
Vpatient-D(e1,e2)	VARIANT and VARIANT each account for around 20% of <e2> DISEASE </e2> alleles in the Dutch patient group, whilst VARIANT, <e1> VARIANT </e1>, VARIANT and VARIANT each have a frequency of about 6% in Australasian patients.
Vpatient-D(e1,e2)	VARIANT and VARIANT each account for around 20% of <e2> DISEASE </e2> alleles in the Dutch patient group, whilst VARIANT, VARIANT, <e1> VARIANT </e1> and VARIANT each have a frequency of about 6% in Australasian patients.
Vpatient-D(e1,e2)	VARIANT and VARIANT each account for around 20% of <e2> DISEASE </e2> alleles in the Dutch patient group, whilst VARIANT, VARIANT, VARIANT and <e1> VARIANT </e1> each have a frequency of about 6% in Australasian patients.
Vpatient-D(e1,e2)	MEFV-Gene analysis in armenian patients with <e2> DISEASE </e2>: diagnostic value and unfavorable renal prognosis of the <e1> VARIANT </e1> homozygous genotype-genetic and therapeutic implications.
Vpositive-D(e1,e2)	The <e1> VARIANT </e1> homozygous genotype was found to be associated with a higher prevalence of <e2> DISEASE </e2> and DISEASE, compared with other genotypes (P=.0002 and P=.006, respectively).
Vpositive-D(e1,e2)	The <e1> VARIANT </e1> homozygous genotype was found to be associated with a higher prevalence of DISEASE and <e2> DISEASE </e2>, compared with other genotypes (P=.0002 and P=.006, respectively).
Vpatient-D(e1,e2)	Eight mutations, one of which (<e1> VARIANT </e1>) is new, were found to account for 93% of the 163 independent <e2> DISEASE </e2> alleles, with both <e2> DISEASE </e2> alleles identified in 89% of the patients.
Vappositive-D(e1,e2)	These results, showing that the <e1> VARIANT </e1> and VARIANT <e2> DISEASE </e2> mutations both have profound effects on channel activation and fast-slow inactivation, suggest that the S5 segment maybe in a location where fast and slow inactivation converge.
Vappositive-D(e1,e2)	In contrast, the <e1> VARIANT </e1> mutation, a <e2> DISEASE </e2> mutation located in the cytoplasmic interface of the S5 segment of the second domain, also shifted activation in the hyperpolarizing direction but had little effect on fast inactivation and dramatically impaired slow inactivation.
Vappositive-D(e1,e2)	These results, showing that the VARIANT and <e1> VARIANT </e1> <e2> DISEASE </e2> mutations both have profound effects on channel activation and fast-slow inactivation, suggest that the S5 segment maybe in a location where fast and slow inactivation converge.
Vappositive-D(e1,e2)	Radiological analysis of children with <e2> DISEASE </e2> who are homozygous for <e2> DISEASE </e2> transmembrane conductance regulator mutation <e1> VARIANT </e1> (VARIANT).
Vpatient-D(e1,e2)	Detailed radiological analyses were performed by a single observer in 12 children with <e2> DISEASE </e2> from the United Arab Emirates who were homozygous for DISEASE mutation <e1> VARIANT </e1> (VARIANT).
Vpositive-D(e1,e2)	We investigated the extent and severity of <e2> DISEASE </e2> associated with CFTR mutation <e1> VARIANT </e1> (VARIANT).
Vappositive-D(e1,e2)	Detailed radiological analyses were performed by a single observer in 12 children with DISEASE from the United Arab Emirates who were homozygous for <e2> DISEASE </e2> mutation <e1> VARIANT </e1> (VARIANT).
Vappositive-D(e1,e2)	Radiological analysis of children with <e2> DISEASE </e2> who are homozygous for <e2> DISEASE </e2> transmembrane conductance regulator mutation VARIANT (<e1> VARIANT </e1>).
Vpatient-D(e1,e2)	Detailed radiological analyses were performed by a single observer in 12 children with <e2> DISEASE </e2> from the United Arab Emirates who were homozygous for DISEASE mutation VARIANT (<e1> VARIANT </e1>).
Vpositive-D(e1,e2)	We investigated the extent and severity of <e2> DISEASE </e2> associated with CFTR mutation VARIANT (<e1> VARIANT </e1>).
Vappositive-D(e1,e2)	Detailed radiological analyses were performed by a single observer in 12 children with DISEASE from the United Arab Emirates who were homozygous for <e2> DISEASE </e2> mutation VARIANT (<e1> VARIANT </e1>).
Other	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or VARIANT mutation and low group Ret with the <e1> VARIANT </e1>, VARIANT or VARIANT mutation were associated with the development of <e2> DISEASE </e2> and DISEASE, respectively.
Vpositive-D(e1,e2)	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or VARIANT mutation and low group Ret with the <e1> VARIANT </e1>, VARIANT or VARIANT mutation were associated with the development of DISEASE and <e2> DISEASE </e2>, respectively.
Other	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or VARIANT mutation and low group Ret with the VARIANT, <e1> VARIANT </e1> or VARIANT mutation were associated with the development of <e2> DISEASE </e2> and DISEASE, respectively.
Vpositive-D(e1,e2)	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or VARIANT mutation and low group Ret with the VARIANT, <e1> VARIANT </e1> or VARIANT mutation were associated with the development of DISEASE and <e2> DISEASE </e2>, respectively.
Vpositive-D(e1,e2)	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the <e1> VARIANT </e1> or VARIANT mutation and low group Ret with the VARIANT, VARIANT or VARIANT mutation were associated with the development of <e2> DISEASE </e2> and DISEASE, respectively.
Other	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the <e1> VARIANT </e1> or VARIANT mutation and low group Ret with the VARIANT, VARIANT or VARIANT mutation were associated with the development of DISEASE and <e2> DISEASE </e2>, respectively.
Other	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or VARIANT mutation and low group Ret with the VARIANT, VARIANT or <e1> VARIANT </e1> mutation were associated with the development of <e2> DISEASE </e2> and DISEASE, respectively.
Vpositive-D(e1,e2)	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or VARIANT mutation and low group Ret with the VARIANT, VARIANT or <e1> VARIANT </e1> mutation were associated with the development of DISEASE and <e2> DISEASE </e2>, respectively.
Vpositive-D(e1,e2)	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or <e1> VARIANT </e1> mutation and low group Ret with the VARIANT, VARIANT or VARIANT mutation were associated with the development of <e2> DISEASE </e2> and DISEASE, respectively.
Other	Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the VARIANT or <e1> VARIANT </e1> mutation and low group Ret with the VARIANT, VARIANT or VARIANT mutation were associated with the development of DISEASE and <e2> DISEASE </e2>, respectively.
Vappositive-D(e1,e2)	Similarly, in vitro expression studies largely predicted dietary tolerance in compound heterozygotes for the <e1> VARIANT </e1> (typical <e2> DISEASE </e2>), <e1> VARIANT </e1>, VARIANT, and VARIANT mutations (mild variants).
Vpatient-D(e1,e2)	Comparing the predicted residual activity derived from expression studies to the clinical phenotypes of our <e2> DISEASE </e2> patients, we found that homozygosity for the <e1> VARIANT </e1> and VARIANT mutations resulted in severe and mild PAH deficiencies, respectively, both in vivo and in vitro, while compound heterozygosity (<e1> VARIANT </e1>) resulted in an intermediate dietary tolerance.
Vpatient-D(e1,e2)	Comparing the predicted residual activity derived from expression studies to the clinical phenotypes of our <e2> DISEASE </e2> patients, we found that homozygosity for the VARIANT and <e1> VARIANT </e1> mutations resulted in severe and mild PAH deficiencies, respectively, both in vivo and in vitro, while compound heterozygosity (VARIANT) resulted in an intermediate dietary tolerance.
Other	Similarly, in vitro expression studies largely predicted dietary tolerance in compound heterozygotes for the VARIANT (typical <e2> DISEASE </e2>), VARIANT, <e1> VARIANT </e1>, and <e1> VARIANT </e1> mutations (mild variants).
Vpatient-D(e1,e2)	We describe three novel mutations (<e1> VARIANT </e1>, VARIANT, and VARIANT) and one common <e2> DISEASE </e2> mutation (VARIANT), detected by mutational and polymorphism analysis of the HGO gene in five Finnish <e2> DISEASE </e2> pedigrees.
Vpatient-D(e1,e2)	We describe three novel mutations (VARIANT, <e1> VARIANT </e1>, and VARIANT) and one common <e2> DISEASE </e2> mutation (VARIANT), detected by mutational and polymorphism analysis of the HGO gene in five Finnish <e2> DISEASE </e2> pedigrees.
Vpatient-D(e1,e2)	We describe three novel mutations (VARIANT, VARIANT, and <e1> VARIANT </e1>) and one common <e2> DISEASE </e2> mutation (VARIANT), detected by mutational and polymorphism analysis of the HGO gene in five Finnish <e2> DISEASE </e2> pedigrees.
Vappositive-D(e1,e2)	We describe three novel mutations (VARIANT, VARIANT, and VARIANT) and one common <e2> DISEASE </e2> mutation (<e1> VARIANT </e1>), detected by mutational and polymorphism analysis of the HGO gene in five Finnish <e2> DISEASE </e2> pedigrees.
Vpatient-D(e1,e2)	An <e2> DISEASE </e2> quantification system was developed to determine the effect of the three most common and severe patient mutations: <e1> VARIANT </e1> (Italy), VARIANT (Poland), and VARIANT (The Netherlands).
Vpatient-D(e1,e2)	An <e2> DISEASE </e2> quantification system was developed to determine the effect of the three most common and severe patient mutations: VARIANT (Italy), <e1> VARIANT </e1> (Poland), and VARIANT (The Netherlands).
Vpatient-D(e1,e2)	An <e2> DISEASE </e2> quantification system was developed to determine the effect of the three most common and severe patient mutations: VARIANT (Italy), VARIANT (Poland), and <e1> VARIANT </e1> (The Netherlands).
Vpatient-D(e1,e2)	<e2> DISEASE </e2> mutations have been reported at methionine 918 or <e1> VARIANT </e1> kinase domain of the RET proto-oncogene.
Other	Like RET with the VARIANT or VARIANT <e2> DISEASE </e2> mutation, the transforming activity of RET with the <e1> VARIANT </e1> mutation was not affected by substitution of VARIANT that abolished the activity of RET with the DISEASE mutation.
Other	Like RET with the VARIANT or VARIANT DISEASE mutation, the transforming activity of RET with the <e1> VARIANT </e1> mutation was not affected by substitution of VARIANT that abolished the activity of RET with the <e2> DISEASE </e2> mutation.
Other	Like RET with the <e1> VARIANT </e1> or VARIANT <e2> DISEASE </e2> mutation, the transforming activity of RET with the VARIANT mutation was not affected by substitution of VARIANT that abolished the activity of RET with the DISEASE mutation.
Other	Like RET with the <e1> VARIANT </e1> or VARIANT DISEASE mutation, the transforming activity of RET with the VARIANT mutation was not affected by substitution of VARIANT that abolished the activity of RET with the <e2> DISEASE </e2> mutation.
Vappositive-D(e1,e2)	Like RET with the VARIANT or <e1> VARIANT </e1> <e2> DISEASE </e2> mutation, the transforming activity of RET with the VARIANT mutation was not affected by substitution of VARIANT that abolished the activity of RET with the DISEASE mutation.
Other	Like RET with the VARIANT or <e1> VARIANT </e1> DISEASE mutation, the transforming activity of RET with the VARIANT mutation was not affected by substitution of VARIANT that abolished the activity of RET with the <e2> DISEASE </e2> mutation.
Other	Like RET with the VARIANT or VARIANT <e2> DISEASE </e2> mutation, the transforming activity of RET with the VARIANT mutation was not affected by substitution of <e1> VARIANT </e1> that abolished the activity of RET with the DISEASE mutation.
Other	Like RET with the VARIANT or VARIANT DISEASE mutation, the transforming activity of RET with the VARIANT mutation was not affected by substitution of <e1> VARIANT </e1> that abolished the activity of RET with the <e2> DISEASE </e2> mutation.
Vpatient-D(e1,e2)	[Turkish infant with <e2> DISEASE </e2> and DISEASE as the sole manifestations of a mild form of DISEASE (mutation <e1> VARIANT </e1>)].
Vpatient-D(e1,e2)	[Turkish infant with DISEASE and <e2> DISEASE </e2> as the sole manifestations of a mild form of DISEASE (mutation <e1> VARIANT </e1>)].
Vappositive-D(e1,e2)	[Turkish infant with DISEASE and DISEASE as the sole manifestations of a mild form of <e2> DISEASE </e2> (mutation <e1> VARIANT </e1>)].
Vpatient-D(e1,e2)	Since no other signs and symptoms of the <e2> DISEASE </e2> were present, the finding of the rare mutation <e1> VARIANT </e1> on exon 4 of the CFTR-gene was paramount in the delineation of his underlying illness.
Vpositive-D(e1,e2)	Here, we describe as a model system structural and functional consequences of two typical mutations in cbEGF modules of fibrillin-1 (<e1> VARIANT </e1>, VARIANT), resulting in the <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	Here, we describe as a model system structural and functional consequences of two typical mutations in cbEGF modules of fibrillin-1 (VARIANT, <e1> VARIANT </e1>), resulting in the <e2> DISEASE </e2>.
Vappositive-D(e1,e2)	We have analyzed the functional effects of two <e2> DISEASE </e2> mutations (<e1> VARIANT </e1> and VARIANT) using purified recombinant cTnI.
Vappositive-D(e1,e2)	We have analyzed the functional effects of two <e2> DISEASE </e2> mutations (VARIANT and <e1> VARIANT </e1>) using purified recombinant cTnI.
Vpatient-D(e1,e2)	Characterization of two alpha-galactosidase mutants (<e1> VARIANT </e1> and VARIANT) found in an atypical variant of <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Cultured lymphoblasts, L-57 (<e1> VARIANT </e1>) and L-148 (VARIANT), from patients with variant <e2> DISEASE </e2>, and L-20 (wild-type) from a normal subject were used.
Vappositive-D(e1,e2)	Compared to normal control cells, fibroblast cells from a patient with variant <e2> DISEASE </e2>, <e1> VARIANT </e1> mutation, secreted only small amounts of alpha-galactosidase activity even in the presence of 10 mM NH (4) Cl.
Vpatient-D(e1,e2)	Characterization of two alpha-galactosidase mutants (VARIANT and <e1> VARIANT </e1>) found in an atypical variant of <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Cultured lymphoblasts, L-57 (VARIANT) and L-148 (<e1> VARIANT </e1>), from patients with variant <e2> DISEASE </e2>, and L-20 (wild-type) from a normal subject were used.
Vpatient-D(e1,e2)	A novel missense mutation (<e1> VARIANT </e1>) in the HERG channel, present in the homozygous state in the affected siblings and in the heterozygous state in their parents, as well as in 38 additional subjects from six <e2> DISEASE </e2> families, was identified.
Vappositive-D(e1,e2)	To study the effect of craniosynostosis-linked mutations in osteoblasts, we introduced FGFR2 carrying either the <e1> VARIANT </e1> (<e2> DISEASE </e2>) or the VARIANT (DISEASE) mutation in OB1 cells.
Other	To study the effect of craniosynostosis-linked mutations in osteoblasts, we introduced FGFR2 carrying either the <e1> VARIANT </e1> (DISEASE) or the VARIANT (<e2> DISEASE </e2>) mutation in OB1 cells.
Other	To study the effect of craniosynostosis-linked mutations in osteoblasts, we introduced FGFR2 carrying either the VARIANT (<e2> DISEASE </e2>) or the <e1> VARIANT </e1> (DISEASE) mutation in OB1 cells.
Vappositive-D(e1,e2)	To study the effect of craniosynostosis-linked mutations in osteoblasts, we introduced FGFR2 carrying either the VARIANT (DISEASE) or the <e1> VARIANT </e1> (<e2> DISEASE </e2>) mutation in OB1 cells.
Vpatient-D(e1,e2)	Enzymatic mutation detection (EMD) of novel mutations (<e1> VARIANT </e1> and VARIANT) in the FBN1 gene of patients with <e2> DISEASE </e2> using T4 endonuclease VII.
Vpositive-D(e1,e2)	Two causative mutations, <e1> VARIANT </e1> and VARIANT, were detected by <e2> DISEASE </e2> that were not detected by MDE.
Vpatient-D(e1,e2)	Enzymatic mutation detection (EMD) of novel mutations (VARIANT and <e1> VARIANT </e1>) in the FBN1 gene of patients with <e2> DISEASE </e2> using T4 endonuclease VII.
Vpositive-D(e1,e2)	Two causative mutations, VARIANT and <e1> VARIANT </e1>, were detected by <e2> DISEASE </e2> that were not detected by MDE.
Vpatient-D(e1,e2)	We found two new mutations and one recently described mutation in the cathepsin K gene by sequencing DNA from eight patients with <e2> DISEASE </e2>: a one base transition in exon8, <e1> VARIANT </e1>, causing a single amino acid substitution VARIANT, VARIANT; A 3' splice site mutation in intron 2, VARIANT, causing deletion of all exon 3, 41V-81Mdel; and the exon 3 missense mutation VARIANT leading to residue VARIANT.
Vpatient-D(e1,e2)	We found two new mutations and one recently described mutation in the cathepsin K gene by sequencing DNA from eight patients with <e2> DISEASE </e2>: a one base transition in exon8, VARIANT, causing a single amino acid substitution <e1> VARIANT </e1>, VARIANT; A 3' splice site mutation in intron 2, VARIANT, causing deletion of all exon 3, 41V-81Mdel; and the exon 3 missense mutation VARIANT leading to residue VARIANT.
Vpatient-D(e1,e2)	We found two new mutations and one recently described mutation in the cathepsin K gene by sequencing DNA from eight patients with <e2> DISEASE </e2>: a one base transition in exon8, VARIANT, causing a single amino acid substitution VARIANT, <e1> VARIANT </e1>; A 3' splice site mutation in intron 2, VARIANT, causing deletion of all exon 3, 41V-81Mdel; and the exon 3 missense mutation VARIANT leading to residue VARIANT.
Vpatient-D(e1,e2)	We found two new mutations and one recently described mutation in the cathepsin K gene by sequencing DNA from eight patients with <e2> DISEASE </e2>: a one base transition in exon8, VARIANT, causing a single amino acid substitution VARIANT, VARIANT; A 3' splice site mutation in intron 2, <e1> VARIANT </e1>, causing deletion of all exon 3, 41V-81Mdel; and the exon 3 missense mutation VARIANT leading to residue VARIANT.
Vpatient-D(e1,e2)	We found two new mutations and one recently described mutation in the cathepsin K gene by sequencing DNA from eight patients with <e2> DISEASE </e2>: a one base transition in exon8, VARIANT, causing a single amino acid substitution VARIANT, VARIANT; A 3' splice site mutation in intron 2, VARIANT, causing deletion of all exon 3, 41V-81Mdel; and the exon 3 missense mutation <e1> VARIANT </e1> leading to residue VARIANT.
Vpatient-D(e1,e2)	We found two new mutations and one recently described mutation in the cathepsin K gene by sequencing DNA from eight patients with <e2> DISEASE </e2>: a one base transition in exon8, VARIANT, causing a single amino acid substitution VARIANT, VARIANT; A 3' splice site mutation in intron 2, VARIANT, causing deletion of all exon 3, 41V-81Mdel; and the exon 3 missense mutation VARIANT leading to residue <e1> VARIANT </e1>.
Vpositive-D(e1,e2)	The biophysical properties of the SCN5A mutation <e1> VARIANT </e1> associated with <e2> DISEASE </e2> were examined for defects in intermediate inactivation (I: (M)), a gating process in Na (+) channels with kinetic features intermediate between fast and slow inactivation.
Vpositive-D(e1,e2)	In vitro expression studies on <e1> VARIANT </e1> and VARIANT mutations causing mild <e2> DISEASE </e2> are presented.
Vpositive-D(e1,e2)	In vitro expression studies on VARIANT and <e1> VARIANT </e1> mutations causing mild <e2> DISEASE </e2> are presented.
Vappositive-D(e1,e2)	The effect of the <e2> DISEASE </e2> mutations, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, and VARIANT, found in the regulatory light chains of human cardiac myosin has been investigated.
Vappositive-D(e1,e2)	The effect of the <e2> DISEASE </e2> mutations, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT, found in the regulatory light chains of human cardiac myosin has been investigated.
Vappositive-D(e1,e2)	The effect of the <e2> DISEASE </e2> mutations, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT, found in the regulatory light chains of human cardiac myosin has been investigated.
Vappositive-D(e1,e2)	The effect of the <e2> DISEASE </e2> mutations, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT, found in the regulatory light chains of human cardiac myosin has been investigated.
Vappositive-D(e1,e2)	The effect of the <e2> DISEASE </e2> mutations, VARIANT, VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>, found in the regulatory light chains of human cardiac myosin has been investigated.
Other	We therefore believe <e1> VARIANT </e1> to be a more malignant missense mutation, probably linked with DISEASE in the affected family, than VARIANT, which seems to be more benign causing late-onset <e2> DISEASE </e2> and mild clinical symptoms in the affected family members.
Vpositive-D(e1,e2)	We therefore believe <e1> VARIANT </e1> to be a more malignant missense mutation, probably linked with <e2> DISEASE </e2> in the affected family, than VARIANT, which seems to be more benign causing late-onset DISEASE and mild clinical symptoms in the affected family members.
Vpositive-D(e1,e2)	We therefore believe VARIANT to be a more malignant missense mutation, probably linked with DISEASE in the affected family, than <e1> VARIANT </e1>, which seems to be more benign causing late-onset <e2> DISEASE </e2> and mild clinical symptoms in the affected family members.
Vpositive-D(e1,e2)	We therefore believe VARIANT to be a more malignant missense mutation, probably linked with <e2> DISEASE </e2> in the affected family, than <e1> VARIANT </e1>, which seems to be more benign causing late-onset DISEASE and mild clinical symptoms in the affected family members.
Vpositive-D(e1,e2)	We report a case of a novel HERG mutation (<e1> VARIANT </e1>) that caused a <e2> DISEASE </e2> form of DISEASE.
Vpositive-D(e1,e2)	We report a case of a novel HERG mutation (<e1> VARIANT </e1>) that caused a DISEASE form of <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	<e1> VARIANT </e1> and VARIANT mutant beta-cardiac myosin from patients with <e2> DISEASE </e2> exhibit enhanced mechanical performance at the single molecule level.
Vpatient-D(e1,e2)	VARIANT and <e1> VARIANT </e1> mutant beta-cardiac myosin from patients with <e2> DISEASE </e2> exhibit enhanced mechanical performance at the single molecule level.
Vpatient-D(e1,e2)	We evaluated the clinical data obtained from a multidisciplinary trial of 11 patients with <e2> DISEASE </e2> who presented with nine new mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, N61/I62/T63fsdel5bp, VARIANT, VARIANT, H1OOR, VARIANT and VARIANT) identified during a molecular study of the PAH gene done in Catalonia (Spain).
Vpatient-D(e1,e2)	We evaluated the clinical data obtained from a multidisciplinary trial of 11 patients with <e2> DISEASE </e2> who presented with nine new mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, N61/I62/T63fsdel5bp, VARIANT, VARIANT, H1OOR, VARIANT and VARIANT) identified during a molecular study of the PAH gene done in Catalonia (Spain).
Vpatient-D(e1,e2)	We evaluated the clinical data obtained from a multidisciplinary trial of 11 patients with <e2> DISEASE </e2> who presented with nine new mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, N61/I62/T63fsdel5bp, VARIANT, VARIANT, H1OOR, VARIANT and VARIANT) identified during a molecular study of the PAH gene done in Catalonia (Spain).
Vpatient-D(e1,e2)	We evaluated the clinical data obtained from a multidisciplinary trial of 11 patients with <e2> DISEASE </e2> who presented with nine new mutations (VARIANT, VARIANT, VARIANT, N61/I62/T63fsdel5bp, <e1> VARIANT </e1>, VARIANT, H1OOR, VARIANT and VARIANT) identified during a molecular study of the PAH gene done in Catalonia (Spain).
Vpatient-D(e1,e2)	We evaluated the clinical data obtained from a multidisciplinary trial of 11 patients with <e2> DISEASE </e2> who presented with nine new mutations (VARIANT, VARIANT, VARIANT, N61/I62/T63fsdel5bp, VARIANT, <e1> VARIANT </e1>, H1OOR, VARIANT and VARIANT) identified during a molecular study of the PAH gene done in Catalonia (Spain).
Vpatient-D(e1,e2)	We evaluated the clinical data obtained from a multidisciplinary trial of 11 patients with <e2> DISEASE </e2> who presented with nine new mutations (VARIANT, VARIANT, VARIANT, N61/I62/T63fsdel5bp, VARIANT, VARIANT, H1OOR, <e1> VARIANT </e1> and VARIANT) identified during a molecular study of the PAH gene done in Catalonia (Spain).
Vpatient-D(e1,e2)	We evaluated the clinical data obtained from a multidisciplinary trial of 11 patients with <e2> DISEASE </e2> who presented with nine new mutations (VARIANT, VARIANT, VARIANT, N61/I62/T63fsdel5bp, VARIANT, VARIANT, H1OOR, VARIANT and <e1> VARIANT </e1>) identified during a molecular study of the PAH gene done in Catalonia (Spain).
Vpositive-D(e1,e2)	Biochemical basis for the dominant inheritance of <e2> DISEASE </e2> associated with the <e1> VARIANT </e1> mutation of the MAT1A gene.
Vpositive-D(e1,e2)	Moreover, our results provide a molecular mechanism that might explain the dominant inheritance of the <e2> DISEASE </e2> associated with the <e1> VARIANT </e1> mutation of human MAT I/III.
Vpositive-D(e1,e2)	The only exception is the dominant mild <e2> DISEASE </e2> associated with a <e1> VARIANT </e1> of exon VII.
Vappositive-D(e1,e2)	In <e2> DISEASE </e2> the RET gene is mutated in codon 918, where a methionine is substituted to a threonine (<e1> VARIANT </e1>).
Vappositive-D(e1,e2)	We report here novel <e2> DISEASE </e2> mutant proteins (<e1> VARIANT </e1>, VARIANT and VARIANT) in Danish <e2> DISEASE </e2> patients.
Vappositive-D(e1,e2)	We report here novel <e2> DISEASE </e2> mutant proteins (VARIANT, <e1> VARIANT </e1> and VARIANT) in Danish <e2> DISEASE </e2> patients.
Vappositive-D(e1,e2)	We report here novel <e2> DISEASE </e2> mutant proteins (VARIANT, VARIANT and <e1> VARIANT </e1>) in Danish <e2> DISEASE </e2> patients.
Vappositive-D(e1,e2)	We have applied a yeast two-hybrid method, in which protein--protein interactions are measured by four reporter gene constructs, to the analysis of six <e2> DISEASE </e2> PAH missense mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT).
Vappositive-D(e1,e2)	We have applied a yeast two-hybrid method, in which protein--protein interactions are measured by four reporter gene constructs, to the analysis of six <e2> DISEASE </e2> PAH missense mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, and VARIANT).
Vappositive-D(e1,e2)	We have applied a yeast two-hybrid method, in which protein--protein interactions are measured by four reporter gene constructs, to the analysis of six <e2> DISEASE </e2> PAH missense mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT).
Vappositive-D(e1,e2)	We have applied a yeast two-hybrid method, in which protein--protein interactions are measured by four reporter gene constructs, to the analysis of six <e2> DISEASE </e2> PAH missense mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT).
Vappositive-D(e1,e2)	We have applied a yeast two-hybrid method, in which protein--protein interactions are measured by four reporter gene constructs, to the analysis of six <e2> DISEASE </e2> PAH missense mutations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT).
Vappositive-D(e1,e2)	We have applied a yeast two-hybrid method, in which protein--protein interactions are measured by four reporter gene constructs, to the analysis of six <e2> DISEASE </e2> PAH missense mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>).
Vpatient-D(e1,e2)	Five founder mutations, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT and VARIANT account for 74% of <e2> DISEASE </e2> chromosomes from typical cases (Armenians, Arabs, Jews, and Turks).
Vpatient-D(e1,e2)	Five founder mutations, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT and VARIANT account for 74% of <e2> DISEASE </e2> chromosomes from typical cases (Armenians, Arabs, Jews, and Turks).
Vpatient-D(e1,e2)	Five founder mutations, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT and VARIANT account for 74% of <e2> DISEASE </e2> chromosomes from typical cases (Armenians, Arabs, Jews, and Turks).
Vpatient-D(e1,e2)	Five founder mutations, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1> and VARIANT account for 74% of <e2> DISEASE </e2> chromosomes from typical cases (Armenians, Arabs, Jews, and Turks).
Vpatient-D(e1,e2)	Five founder mutations, VARIANT, VARIANT, VARIANT, VARIANT and <e1> VARIANT </e1> account for 74% of <e2> DISEASE </e2> chromosomes from typical cases (Armenians, Arabs, Jews, and Turks).
Vpatient-D(e1,e2)	However, skewed X-chromosome inactivation was not detected in either the lymphocyte or muscle DNA of a woman who presented with <e2> DISEASE </e2> and was found to be heterozygous for the <e1> VARIANT </e1> mutation.
Vpatient-D(e1,e2)	In family A a missense mutation (nucleotide <e1> VARIANT </e1>, amino acid VARIANT) was identified in 14 adult subjects; disease was manifest as progressive <e2> DISEASE </e2> in the fourth and fifth decades.
Vpatient-D(e1,e2)	In family A a missense mutation (nucleotide VARIANT, amino acid <e1> VARIANT </e1>) was identified in 14 adult subjects; disease was manifest as progressive <e2> DISEASE </e2> in the fourth and fifth decades.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide <e1> VARIANT </e1>, amino acid VARIANT) was identified in 10 adult subjects; disease was also manifest as progressive <e2> DISEASE </e2> but with earlier onset (third and fourth decades), DISEASE, DISEASE, and DISEASE.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide <e1> VARIANT </e1>, amino acid VARIANT) was identified in 10 adult subjects; disease was also manifest as progressive DISEASE but with earlier onset (third and fourth decades), <e2> DISEASE </e2>, DISEASE, and DISEASE.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide <e1> VARIANT </e1>, amino acid VARIANT) was identified in 10 adult subjects; disease was also manifest as progressive DISEASE but with earlier onset (third and fourth decades), DISEASE, <e2> DISEASE </e2>, and DISEASE.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide <e1> VARIANT </e1>, amino acid VARIANT) was identified in 10 adult subjects; disease was also manifest as progressive DISEASE but with earlier onset (third and fourth decades), DISEASE, DISEASE, and <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide VARIANT, amino acid <e1> VARIANT </e1>) was identified in 10 adult subjects; disease was also manifest as progressive <e2> DISEASE </e2> but with earlier onset (third and fourth decades), DISEASE, DISEASE, and DISEASE.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide VARIANT, amino acid <e1> VARIANT </e1>) was identified in 10 adult subjects; disease was also manifest as progressive DISEASE but with earlier onset (third and fourth decades), <e2> DISEASE </e2>, DISEASE, and DISEASE.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide VARIANT, amino acid <e1> VARIANT </e1>) was identified in 10 adult subjects; disease was also manifest as progressive DISEASE but with earlier onset (third and fourth decades), DISEASE, <e2> DISEASE </e2>, and DISEASE.
Vpatient-D(e1,e2)	In family B a nonsense mutation (nucleotide VARIANT, amino acid <e1> VARIANT </e1>) was identified in 10 adult subjects; disease was also manifest as progressive DISEASE but with earlier onset (third and fourth decades), DISEASE, DISEASE, and <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	A <e1> VARIANT </e1> mutation in the CTNS gene is a common cause of <e2> DISEASE </e2> in the south western Ontario Amish Mennonite population.
Vpatient-D(e1,e2)	A previously reported mutation (<e1> VARIANT </e1>) was detected in three <e2> DISEASE </e2> patients from two families.
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT).
Vpatient-D(e1,e2)	In total, 165 of the 170 mutant alleles were identified in this study and despite the high frequency of VARIANT and <e1> VARIANT </e1>, the identification of many novel mutations unique to individual families further highlights the genetic heterogeneity of <e2> DISEASE </e2> I.
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT).
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT).
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT).
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT).
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT).
Vpatient-D(e1,e2)	In total, 165 of the 170 mutant alleles were identified in this study and despite the high frequency of <e1> VARIANT </e1> and VARIANT, the identification of many novel mutations unique to individual families further highlights the genetic heterogeneity of <e2> DISEASE </e2> I.
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT).
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT).
Other	In this study, 85 <e2> DISEASE </e2> families (73 Hurler, 5 Hurler/Scheie, 7 Scheie) were screened for 9 known mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>).
Vpositive-D(e1,e2)	Functional consequences of the six mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause <e2> DISEASE </e2> DISEASE (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE <e2> DISEASE </e2> (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE DISEASE (<e2> DISEASE </e2>) were studied using purified recombinant human cTnI.
Other	These results demonstrated that most of the <e2> DISEASE </e2> cTnI mutations did affect the regulatory processes involving the cTnI molecule, and that at least five mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, DeltaK183, VARIANT) increased the Ca (2+) sensitivity of cardiac muscle contraction.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause <e2> DISEASE </e2> DISEASE (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE <e2> DISEASE </e2> (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE DISEASE (<e2> DISEASE </e2>) were studied using purified recombinant human cTnI.
Other	These results demonstrated that most of the <e2> DISEASE </e2> cTnI mutations did affect the regulatory processes involving the cTnI molecule, and that at least five mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, DeltaK183, VARIANT) increased the Ca (2+) sensitivity of cardiac muscle contraction.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause <e2> DISEASE </e2> DISEASE (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE <e2> DISEASE </e2> (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE DISEASE (<e2> DISEASE </e2>) were studied using purified recombinant human cTnI.
Other	These results demonstrated that most of the <e2> DISEASE </e2> cTnI mutations did affect the regulatory processes involving the cTnI molecule, and that at least five mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, DeltaK183, VARIANT) increased the Ca (2+) sensitivity of cardiac muscle contraction.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause <e2> DISEASE </e2> DISEASE (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE <e2> DISEASE </e2> (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE DISEASE (<e2> DISEASE </e2>) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT) in cardiac troponin I (cTnI) that cause <e2> DISEASE </e2> DISEASE (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE <e2> DISEASE </e2> (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT) in cardiac troponin I (cTnI) that cause DISEASE DISEASE (<e2> DISEASE </e2>) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>) in cardiac troponin I (cTnI) that cause <e2> DISEASE </e2> DISEASE (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>) in cardiac troponin I (cTnI) that cause DISEASE <e2> DISEASE </e2> (DISEASE) were studied using purified recombinant human cTnI.
Vpositive-D(e1,e2)	Functional consequences of the six mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>) in cardiac troponin I (cTnI) that cause DISEASE DISEASE (<e2> DISEASE </e2>) were studied using purified recombinant human cTnI.
Other	These results demonstrated that most of the <e2> DISEASE </e2> cTnI mutations did affect the regulatory processes involving the cTnI molecule, and that at least five mutations (VARIANT, VARIANT, VARIANT, DeltaK183, <e1> VARIANT </e1>) increased the Ca (2+) sensitivity of cardiac muscle contraction.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vappositive-D(e1,e2)	Mutations <e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT, located at the carboxyl-terminal end of the <e2> DISEASE </e2> gene, were found to inhibit alpha-beta heteromeric and/or the beta-beta homomeric interaction independently of the cultivation temperature, reflecting their primary effect on the assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vappositive-D(e1,e2)	Mutations VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT, located at the carboxyl-terminal end of the <e2> DISEASE </e2> gene, were found to inhibit alpha-beta heteromeric and/or the beta-beta homomeric interaction independently of the cultivation temperature, reflecting their primary effect on the assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vappositive-D(e1,e2)	Mutations VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT, located at the carboxyl-terminal end of the <e2> DISEASE </e2> gene, were found to inhibit alpha-beta heteromeric and/or the beta-beta homomeric interaction independently of the cultivation temperature, reflecting their primary effect on the assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vappositive-D(e1,e2)	Mutations VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>, located at the carboxyl-terminal end of the <e2> DISEASE </e2> gene, were found to inhibit alpha-beta heteromeric and/or the beta-beta homomeric interaction independently of the cultivation temperature, reflecting their primary effect on the assembly.
Vpositive-D(e1,e2)	To clarify the molecular effect associated with gene alterations causing <e2> DISEASE </e2>, 12 different mutations affecting the PCCB gene (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>) were analyzed for their involvement in alpha-beta heteromeric and beta-beta homomeric assembly.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, and VARIANT) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpatient-D(e1,e2)	Eight mutations with a frequency above 1% (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>) accounted for 78% of <e2> DISEASE </e2> chromosomes and have been recommended for inclusion in the CFTR mutation screening panel for molecular diagnosis of <e2> DISEASE </e2> in this region.
Vpositive-D(e1,e2)	Novel cationic trypsinogen (PRSS1) <e1> VARIANT </e1> and VARIANT mutations cause <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	Novel cationic trypsinogen (PRSS1) VARIANT and <e1> VARIANT </e1> mutations cause <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	DISEASE (<e2> DISEASE </e2>) is usually caused by mutations in the cationic trypsinogen (PRSS1) gene, especially <e1> VARIANT </e1> or VARIANT.
Vpositive-D(e1,e2)	<e2> DISEASE </e2> (DISEASE) is usually caused by mutations in the cationic trypsinogen (PRSS1) gene, especially <e1> VARIANT </e1> or VARIANT.
Vpositive-D(e1,e2)	DISEASE (<e2> DISEASE </e2>) is usually caused by mutations in the cationic trypsinogen (PRSS1) gene, especially VARIANT or <e1> VARIANT </e1>.
Vpositive-D(e1,e2)	<e2> DISEASE </e2> (DISEASE) is usually caused by mutations in the cationic trypsinogen (PRSS1) gene, especially VARIANT or <e1> VARIANT </e1>.
Vpositive-D(e1,e2)	Point mutations that cause <e2> DISEASE </e2> (<e1> VARIANT </e1> and VARIANT) and DISEASE (VARIANT) modify the assembly properties of lamins A and C and cause partial mislocalization of emerin, an inner nuclear membrane protein, in HeLa cells.
Other	Point mutations that cause DISEASE (<e1> VARIANT </e1> and VARIANT) and <e2> DISEASE </e2> (VARIANT) modify the assembly properties of lamins A and C and cause partial mislocalization of emerin, an inner nuclear membrane protein, in HeLa cells.
Vpositive-D(e1,e2)	Point mutations that cause <e2> DISEASE </e2> (VARIANT and <e1> VARIANT </e1>) and DISEASE (VARIANT) modify the assembly properties of lamins A and C and cause partial mislocalization of emerin, an inner nuclear membrane protein, in HeLa cells.
Other	Point mutations that cause DISEASE (VARIANT and <e1> VARIANT </e1>) and <e2> DISEASE </e2> (VARIANT) modify the assembly properties of lamins A and C and cause partial mislocalization of emerin, an inner nuclear membrane protein, in HeLa cells.
Other	Point mutations that cause <e2> DISEASE </e2> (VARIANT and VARIANT) and DISEASE (<e1> VARIANT </e1>) modify the assembly properties of lamins A and C and cause partial mislocalization of emerin, an inner nuclear membrane protein, in HeLa cells.
Vpositive-D(e1,e2)	Point mutations that cause DISEASE (VARIANT and VARIANT) and <e2> DISEASE </e2> (<e1> VARIANT </e1>) modify the assembly properties of lamins A and C and cause partial mislocalization of emerin, an inner nuclear membrane protein, in HeLa cells.
Vpositive-D(e1,e2)	By contrast, lamin A and C molecules harboring a point mutation (<e1> VARIANT </e1>), which gives rise to a dominant form of <e2> DISEASE </e2>, behave in a manner that is indistinguishable from wild-type lamins A and C, at least with respect to targeting and assembly within the nuclear lamina.
Other	A naturally occurring mutation (<e1> VARIANT </e1>) in the IQ domain altered hH1 function in a manner characteristic of the <e2> DISEASE </e2>, but at the same time inhibited slow inactivation induced by Ca2+/CaM, yielding a clinically benign (DISEASE free) phenotype.
Other	A naturally occurring mutation (<e1> VARIANT </e1>) in the IQ domain altered hH1 function in a manner characteristic of the DISEASE, but at the same time inhibited slow inactivation induced by Ca2+/CaM, yielding a clinically benign (<e2> DISEASE </e2> free) phenotype.
Vappositive-D(e1,e2)	An <e2> DISEASE </e2> mutation, <e1> VARIANT </e1>, which removes a calcium ligand in cbEGF32, does not detectably affect fibrillin-1 biosynthesis, rate of secretion, processing, or deposition of reducible fibrillin-1 into the ECM.
Vpatient-D(e1,e2)	Five sequence alterations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Homozygotes for the <e1> VARIANT </e1> mutation and the complex VARIANT allele are the most severely affected and often endure <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Five sequence alterations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Homozygotes for the VARIANT mutation and the complex <e1> VARIANT </e1> allele are the most severely affected and often endure <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Five sequence alterations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Five sequence alterations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1> and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Five sequence alterations (VARIANT, VARIANT, VARIANT, VARIANT and <e1> VARIANT </e1>), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six sequence alterations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six sequence alterations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six sequence alterations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six sequence alterations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six sequence alterations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six sequence alterations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>), in the MEFV gene, account for the majority of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	We report two new patients with tetrahydrobiopterin (BH4) -responsive <e2> DISEASE </e2> and compare their phenylalanine hydroxylase (PAH) genotypes (<e1> VARIANT </e1> VARIANT and VARIANT, respectively) to those of previous cases from the literature.
Vpatient-D(e1,e2)	We report two new patients with tetrahydrobiopterin (BH4) -responsive <e2> DISEASE </e2> and compare their phenylalanine hydroxylase (PAH) genotypes (VARIANT <e1> VARIANT </e1> and VARIANT, respectively) to those of previous cases from the literature.
Vpatient-D(e1,e2)	We report two new patients with tetrahydrobiopterin (BH4) -responsive <e2> DISEASE </e2> and compare their phenylalanine hydroxylase (PAH) genotypes (VARIANT VARIANT and <e1> VARIANT </e1>, respectively) to those of previous cases from the literature.
Vpatient-D(e1,e2)	The <e2> DISEASE </e2> gene (MEFV) mutation found in our patients is <e1> VARIANT </e1>.
Vpositive-D(e1,e2)	In the cardiac troponin T gene (TNNT2), a specific mutation (<e1> VARIANT </e1>) has been associated with high risk of <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	<e2> DISEASE </e2>: detection of the IKBKAP <e1> VARIANT </e1> and VARIANT mutations and frequencies among Ashkenazi Jews.
Vpatient-D(e1,e2)	The splice site mutation <e1> VARIANT </e1> is responsible for> 99.5% of known <e2> DISEASE </e2> patients with DISEASE, and haplotype analyses were consistent with a common founder.
Vpatient-D(e1,e2)	Two IKBKAP mutations, <e1> VARIANT </e1> and VARIANT, have been identified in <e2> DISEASE </e2> patients of AJ descent.
Vpatient-D(e1,e2)	The splice site mutation <e1> VARIANT </e1> is responsible for> 99.5% of known DISEASE patients with <e2> DISEASE </e2>, and haplotype analyses were consistent with a common founder.
Vpatient-D(e1,e2)	<e2> DISEASE </e2>: detection of the IKBKAP VARIANT and <e1> VARIANT </e1> mutations and frequencies among Ashkenazi Jews.
Vpatient-D(e1,e2)	In contrast, the <e1> VARIANT </e1> mutation has been identified in only a few <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Two IKBKAP mutations, VARIANT and <e1> VARIANT </e1>, have been identified in <e2> DISEASE </e2> patients of AJ descent.
Vpatient-D(e1,e2)	Six mutations in the <e2> DISEASE </e2> gene were identified, including two novel (<e1> VARIANT </e1> and VARIANT) and four known missense mutations (VARIANT, VARIANT, VARIANT, and VARIANT).
Vpatient-D(e1,e2)	Six mutations in the <e2> DISEASE </e2> gene were identified, including two novel (VARIANT and <e1> VARIANT </e1>) and four known missense mutations (VARIANT, VARIANT, VARIANT, and VARIANT).
Vpatient-D(e1,e2)	Six mutations in the <e2> DISEASE </e2> gene were identified, including two novel (VARIANT and VARIANT) and four known missense mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT).
Vpatient-D(e1,e2)	Six mutations in the <e2> DISEASE </e2> gene were identified, including two novel (VARIANT and VARIANT) and four known missense mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT).
Vpatient-D(e1,e2)	Six mutations in the <e2> DISEASE </e2> gene were identified, including two novel (VARIANT and VARIANT) and four known missense mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT).
Vpatient-D(e1,e2)	Six mutations in the <e2> DISEASE </e2> gene were identified, including two novel (VARIANT and VARIANT) and four known missense mutations (VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>).
Vpatient-D(e1,e2)	All three cases of <e2> DISEASE </e2> reported here have a <e1> VARIANT </e1> mutation in the PTPN11 gene.
Vpositive-D(e1,e2)	We hypothesise that some PTPN11 mutations are associated with the typical <e2> DISEASE </e2> phenotype and that other mutations, such as the <e1> VARIANT </e1> mutation reported here, are associated with both the <e2> DISEASE </e2> phenotype and with DISEASE, such as multiple lentigines or DISEASE.
Vpositive-D(e1,e2)	We hypothesise that some PTPN11 mutations are associated with the typical DISEASE phenotype and that other mutations, such as the <e1> VARIANT </e1> mutation reported here, are associated with both the DISEASE phenotype and with <e2> DISEASE </e2>, such as multiple lentigines or DISEASE.
Vpositive-D(e1,e2)	We hypothesise that some PTPN11 mutations are associated with the typical DISEASE phenotype and that other mutations, such as the <e1> VARIANT </e1> mutation reported here, are associated with both the DISEASE phenotype and with DISEASE, such as multiple lentigines or <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	We describe three novel mutations (<e1> VARIANT </e1>, VARIANT, and VARIANT) in seven <e2> DISEASE </e2> families.
Vpatient-D(e1,e2)	One of these mutations, <e1> VARIANT </e1>, was found in the vast majority of <e2> DISEASE </e2> patients in Israel.
Vpatient-D(e1,e2)	We describe three novel mutations (VARIANT, <e1> VARIANT </e1>, and VARIANT) in seven <e2> DISEASE </e2> families.
Vpatient-D(e1,e2)	We describe three novel mutations (VARIANT, VARIANT, and <e1> VARIANT </e1>) in seven <e2> DISEASE </e2> families.
Vpatient-D(e1,e2)	The so-called common <e1> VARIANT </e1> was found in three alleles, confirming its relative rarity among Italian <e2> DISEASE </e2> families.
Vpatient-D(e1,e2)	Alleleic frequency of <e1> VARIANT </e1> in Korean patients with <e2> DISEASE </e2> was 56.3% in this study.
Other	Molecular analysis in 23 Italian patients with DISEASE identified two novel (<e1> VARIANT </e1>, VARIANT) and 20 previously described <e2> DISEASE </e2> in the PAH gene.
Vpatient-D(e1,e2)	Molecular analysis in 23 Italian patients with <e2> DISEASE </e2> identified two novel (<e1> VARIANT </e1>, VARIANT) and 20 previously described DISEASE in the PAH gene.
Other	Molecular analysis in 23 Italian patients with DISEASE identified two novel (VARIANT, <e1> VARIANT </e1>) and 20 previously described <e2> DISEASE </e2> in the PAH gene.
Vpatient-D(e1,e2)	Molecular analysis in 23 Italian patients with <e2> DISEASE </e2> identified two novel (VARIANT, <e1> VARIANT </e1>) and 20 previously described DISEASE in the PAH gene.
Vpatient-D(e1,e2)	The detection of the <e1> VARIANT </e1> amino acid substitution in combination with null mutations in patients with BH4-responsive <e2> DISEASE </e2> leads us to correlate it with BH4 responsiveness.
Vpositive-D(e1,e2)	A new phenotype for a severe late infantile form of <e2> DISEASE </e2> with DISEASE is associated with compound heterozygosity for the severe <e1> VARIANT </e1> mutation and a mild point mutation (VARIANT).
Vpositive-D(e1,e2)	A new phenotype for a severe late infantile form of DISEASE with <e2> DISEASE </e2> is associated with compound heterozygosity for the severe <e1> VARIANT </e1> mutation and a mild point mutation (VARIANT).
Vpositive-D(e1,e2)	A new phenotype for a severe late infantile form of <e2> DISEASE </e2> with DISEASE is associated with compound heterozygosity for the severe VARIANT mutation and a mild point mutation (<e1> VARIANT </e1>).
Vpositive-D(e1,e2)	A new phenotype for a severe late infantile form of DISEASE with <e2> DISEASE </e2> is associated with compound heterozygosity for the severe VARIANT mutation and a mild point mutation (<e1> VARIANT </e1>).
Vpatient-D(e1,e2)	<e2> DISEASE </e2> phenotype in a German DISEASE family with concurrent DISEASE germline mutations <e1> VARIANT </e1> and VARIANT.
Vpatient-D(e1,e2)	We report on the <e1> VARIANT </e1> germline mutation in a German <e2> DISEASE </e2> family with the previously identified VARIANT mutation.
Vappositive-D(e1,e2)	DISEASE phenotype in a German <e2> DISEASE </e2> family with concurrent <e2> DISEASE </e2> germline mutations <e1> VARIANT </e1> and VARIANT.
Vpatient-D(e1,e2)	<e2> DISEASE </e2> phenotype in a German DISEASE family with concurrent DISEASE germline mutations VARIANT and <e1> VARIANT </e1>.
Vpatient-D(e1,e2)	We report on the VARIANT germline mutation in a German <e2> DISEASE </e2> family with the previously identified <e1> VARIANT </e1> mutation.
Vappositive-D(e1,e2)	DISEASE phenotype in a German <e2> DISEASE </e2> family with concurrent <e2> DISEASE </e2> germline mutations VARIANT and <e1> VARIANT </e1>.
Vpatient-D(e1,e2)	Lack of plasma membrane targeting of a <e1> VARIANT </e1> mutant thiamine transporter derived from <e2> DISEASE </e2> family.
Vpatient-D(e1,e2)	Consequently, the strategy of mutation finding based on screening of recurrent common mutations is limited, as far as regards Italian <e2> DISEASE </e2> patients, to check for the presence of <e1> VARIANT </e1>.
Vpatient-D(e1,e2)	Three members of a Portuguese family, who exhibited clinical evidence of <e2> DISEASE </e2> (NF1), were found to possess different heritable and pathological mutations in their NF1 genes: a 1.5-Mb deletion spanning the entire NF1 gene, a truncating <e1> VARIANT </e1> transition in exon 22 (VARIANT), and a frameshift mutation in exon 29 (VARIANT).
Vpatient-D(e1,e2)	Three members of a Portuguese family, who exhibited clinical evidence of <e2> DISEASE </e2> (NF1), were found to possess different heritable and pathological mutations in their NF1 genes: a 1.5-Mb deletion spanning the entire NF1 gene, a truncating VARIANT transition in exon 22 (<e1> VARIANT </e1>), and a frameshift mutation in exon 29 (VARIANT).
Vpatient-D(e1,e2)	Three members of a Portuguese family, who exhibited clinical evidence of <e2> DISEASE </e2> (NF1), were found to possess different heritable and pathological mutations in their NF1 genes: a 1.5-Mb deletion spanning the entire NF1 gene, a truncating VARIANT transition in exon 22 (VARIANT), and a frameshift mutation in exon 29 (<e1> VARIANT </e1>).
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (<e1> VARIANT </e1>, VARIANT), five recurrent mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT), and four novel mutations (VARIANT, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, <e1> VARIANT </e1>), five recurrent mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT), and four novel mutations (VARIANT, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT), and four novel mutations (VARIANT, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT), and four novel mutations (VARIANT, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT), and four novel mutations (VARIANT, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT), and four novel mutations (VARIANT, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>), and four novel mutations (VARIANT, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT), and four novel mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT), and four novel mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT), and four novel mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT) were identified from <e2> DISEASE </e2> patients.
Vpatient-D(e1,e2)	Eleven different mutations including two common mutations (VARIANT, VARIANT), five recurrent mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT), and four novel mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>) were identified from <e2> DISEASE </e2> patients.
Vpositive-D(e1,e2)	From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHL (<e1> VARIANT </e1>) and pVHL (VARIANT) (that predispose to <e2> DISEASE </e2> and DISEASE, but not to DISEASE) disrupt pVHL's microtubule-stabilizing function.
Vpositive-D(e1,e2)	From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHL (<e1> VARIANT </e1>) and pVHL (VARIANT) (that predispose to DISEASE and <e2> DISEASE </e2>, but not to DISEASE) disrupt pVHL's microtubule-stabilizing function.
Other	From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHL (<e1> VARIANT </e1>) and pVHL (VARIANT) (that predispose to DISEASE and DISEASE, but not to <e2> DISEASE </e2>) disrupt pVHL's microtubule-stabilizing function.
Vpositive-D(e1,e2)	From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHL (VARIANT) and pVHL (<e1> VARIANT </e1>) (that predispose to <e2> DISEASE </e2> and DISEASE, but not to DISEASE) disrupt pVHL's microtubule-stabilizing function.
Vpositive-D(e1,e2)	From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHL (VARIANT) and pVHL (<e1> VARIANT </e1>) (that predispose to DISEASE and <e2> DISEASE </e2>, but not to DISEASE) disrupt pVHL's microtubule-stabilizing function.
Other	From analysis of naturally occurring pVHL mutants, it seems that only point mutations such as pVHL (VARIANT) and pVHL (<e1> VARIANT </e1>) (that predispose to DISEASE and DISEASE, but not to <e2> DISEASE </e2>) disrupt pVHL's microtubule-stabilizing function.
Vpatient-D(e1,e2)	The authors identified missense mutations (<e1> VARIANT </e1>, VARIANT, VARIANT) in the LITAFgene (lipopolysaccharide-induced <e2> DISEASE </e2> necrosis factor-alpha factor) in three DISEASE pedigrees.
Vpatient-D(e1,e2)	The authors identified missense mutations (<e1> VARIANT </e1>, VARIANT, VARIANT) in the LITAFgene (lipopolysaccharide-induced DISEASE necrosis factor-alpha factor) in three <e2> DISEASE </e2> pedigrees.
Vpatient-D(e1,e2)	The authors identified missense mutations (VARIANT, <e1> VARIANT </e1>, VARIANT) in the LITAFgene (lipopolysaccharide-induced <e2> DISEASE </e2> necrosis factor-alpha factor) in three DISEASE pedigrees.
Vpatient-D(e1,e2)	The authors identified missense mutations (VARIANT, <e1> VARIANT </e1>, VARIANT) in the LITAFgene (lipopolysaccharide-induced DISEASE necrosis factor-alpha factor) in three <e2> DISEASE </e2> pedigrees.
Vpatient-D(e1,e2)	The authors identified missense mutations (VARIANT, VARIANT, <e1> VARIANT </e1>) in the LITAFgene (lipopolysaccharide-induced <e2> DISEASE </e2> necrosis factor-alpha factor) in three DISEASE pedigrees.
Vpatient-D(e1,e2)	The authors identified missense mutations (VARIANT, VARIANT, <e1> VARIANT </e1>) in the LITAFgene (lipopolysaccharide-induced DISEASE necrosis factor-alpha factor) in three <e2> DISEASE </e2> pedigrees.
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: <e1> VARIANT </e1> (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	The allele frequency of <e1> VARIANT </e1> in Korean patients with <e2> DISEASE </e2> was 37.9%, which was significantly higher than those of Japanese and Taiwanese patients.
Vpatient-D(e1,e2)	The <e1> VARIANT </e1>, VARIANT, and VARIANT mutations are three major mutations representing approximately 60% of mutated alleles, although Korean patients with <e2> DISEASE </e2> are genetically heterogeneous.
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), <e1> VARIANT </e1> (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	The VARIANT, <e1> VARIANT </e1>, and VARIANT mutations are three major mutations representing approximately 60% of mutated alleles, although Korean patients with <e2> DISEASE </e2> are genetically heterogeneous.
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (<e1> VARIANT </e1>), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	The VARIANT, VARIANT, and <e1> VARIANT </e1> mutations are three major mutations representing approximately 60% of mutated alleles, although Korean patients with <e2> DISEASE </e2> are genetically heterogeneous.
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1> (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), <e1> VARIANT </e1> (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (<e1> VARIANT </e1>), VARIANT (VARIANT), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (<e1> VARIANT </e1>), and VARIANT (VARIANT).
Vpatient-D(e1,e2)	Twelve different mutations in 33 Korean families with <e2> DISEASE </e2> were identified: VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT, VARIANT, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and <e1> VARIANT </e1> (<e1> VARIANT </e1>).
Vpatient-D(e1,e2)	Molecular genetic study in Japanese patients with <e2> DISEASE </e2>: a novel mutation, <e1> VARIANT </e1>.
Vpositive-D(e1,e2)	The results suggest that <e1> VARIANT </e1> may be an important and relatively prevalent disease-causing mutation in Chinese <e2> DISEASE </e2> patients.
Vpositive-D(e1,e2)	<e1> VARIANT </e1> is a recurrent mutation in Chinese <e2> DISEASE </e2> patients which is associated with the late onset phenotype.
Vpatient-D(e1,e2)	Six mutations (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT and VARIANT) represent 92% of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six mutations (VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1> and VARIANT) represent 92% of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	12 different mutations were found, with the most frequent mutation, <e1> VARIANT </e1>, accounting for 76% of Latvian <e2> DISEASE </e2> alleles.
Vpatient-D(e1,e2)	Six mutations (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT) represent 92% of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six mutations (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT and VARIANT) represent 92% of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six mutations (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT and VARIANT) represent 92% of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	Six mutations (VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and <e1> VARIANT </e1>) represent 92% of <e2> DISEASE </e2> chromosomes.
Vpatient-D(e1,e2)	The <e2> DISEASE </e2> from the patient with the <e1> VARIANT </e1> mutation showed a reduced, rather than lost, expression of the MLH1-protein.
Vpatient-D(e1,e2)	Polymorphisms were observed in 48.8% of the <e2> DISEASE </e2> patients, the most frequent being <e1> VARIANT </e1>, VARIANT, and VARIANT.
Vpatient-D(e1,e2)	Polymorphisms were observed in 48.8% of the <e2> DISEASE </e2> patients, the most frequent being VARIANT, <e1> VARIANT </e1>, and VARIANT.
Vpatient-D(e1,e2)	Polymorphisms were observed in 48.8% of the <e2> DISEASE </e2> patients, the most frequent being VARIANT, VARIANT, and <e1> VARIANT </e1>.
Vpatient-D(e1,e2)	Two sisters affected with autosomal-recessive <e2> DISEASE </e2> were shown to be compound heterozygous for two novel GNE mutations: a large deletion involving exons 1-9, and a <e1> VARIANT </e1> amino acid change in the epimerase domain.
Vpositive-D(e1,e2)	Mutations <e1> VARIANT </e1> and VARIANT occurred on different alleles in one individual, and we suggest that these mutations cause <e2> DISEASE </e2> in this patient.
Vpositive-D(e1,e2)	Mutations VARIANT and <e1> VARIANT </e1> occurred on different alleles in one individual, and we suggest that these mutations cause <e2> DISEASE </e2> in this patient.
Vappositive-D(e1,e2)	Four new mutations of the <e2> DISEASE </e2> gene (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT) detected by DGGE analysis in Italian DISEASE patients, associated with different clinical phenotypes.
Vpatient-D(e1,e2)	Four new mutations of the DISEASE gene (<e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT) detected by DGGE analysis in Italian <e2> DISEASE </e2> patients, associated with different clinical phenotypes.
Vappositive-D(e1,e2)	Four new mutations of the <e2> DISEASE </e2> gene (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT) detected by DGGE analysis in Italian DISEASE patients, associated with different clinical phenotypes.
Vpatient-D(e1,e2)	Four new mutations of the DISEASE gene (VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT) detected by DGGE analysis in Italian <e2> DISEASE </e2> patients, associated with different clinical phenotypes.
Vappositive-D(e1,e2)	Four new mutations of the <e2> DISEASE </e2> gene (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT) detected by DGGE analysis in Italian DISEASE patients, associated with different clinical phenotypes.
Vpatient-D(e1,e2)	Four new mutations of the DISEASE gene (VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT) detected by DGGE analysis in Italian <e2> DISEASE </e2> patients, associated with different clinical phenotypes.
Vappositive-D(e1,e2)	Four new mutations of the <e2> DISEASE </e2> gene (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>) detected by DGGE analysis in Italian DISEASE patients, associated with different clinical phenotypes.
Vpatient-D(e1,e2)	Four new mutations of the DISEASE gene (VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>) detected by DGGE analysis in Italian <e2> DISEASE </e2> patients, associated with different clinical phenotypes.
Vpatient-D(e1,e2)	Molecular analyses of the HGO gene mutations in Turkish <e2> DISEASE </e2> patients suggest that the <e1> VARIANT </e1> mutation originated from central Asia and was spread throughout Europe and Anatolia by human migrations.
Vappositive-D(e1,e2)	Most interestingly, these analyses showed that the Turkish <e1> VARIANT </e1> mutation shares an HGO haplotype with the <e1> VARIANT </e1> mutation found in Finland, Slovakia and India, suggesting that <e1> VARIANT </e1> is an old <e2> DISEASE </e2> mutation that probably originated in central Asia and spread throughout Europe and Anatolia during human migrations.
Vpatient-D(e1,e2)	The most common mutations that accounted for the molecular defect in 71.3% of <e2> DISEASE </e2> chromosomes were <e1> VARIANT </e1> (48.9%), VARIANT (11.4%), VARIANT (5.7%), and VARIANT (5.7%).
Vpatient-D(e1,e2)	The most common mutations that accounted for the molecular defect in 71.3% of <e2> DISEASE </e2> chromosomes were VARIANT (48.9%), <e1> VARIANT </e1> (11.4%), VARIANT (5.7%), and VARIANT (5.7%).
Vpatient-D(e1,e2)	The most common mutations that accounted for the molecular defect in 71.3% of <e2> DISEASE </e2> chromosomes were VARIANT (48.9%), VARIANT (11.4%), <e1> VARIANT </e1> (5.7%), and VARIANT (5.7%).
Vpatient-D(e1,e2)	The most common mutations that accounted for the molecular defect in 71.3% of <e2> DISEASE </e2> chromosomes were VARIANT (48.9%), VARIANT (11.4%), VARIANT (5.7%), and <e1> VARIANT </e1> (5.7%).
Vpatient-D(e1,e2)	Evidence for <e1> VARIANT </e1> mutation of the CHRNA4 in a white family with <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	This is the first report of an occurrence of <e1> VARIANT </e1> transition in a white family with <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	<e1> VARIANT </e1> introduces a MaeI restriction endonuclease site into MPS-I alleles enabling its simple detection, which should make possible the assessment of the efficacy of bone marrow transplantation in <e2> DISEASE </e2> patients homozygous for <e1> VARIANT </e1>.
Vpositive-D(e1,e2)	alpha-L-iduronidase mutations (<e1> VARIANT </e1> and VARIANT) associate with a severe <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Allele specific oligonucleotides were used to detect the mutations in a group of 73 <e2> DISEASE </e2> patients and <e1> VARIANT </e1> was found to account for 15% of all DISEASE alleles and VARIANT for 3% of DISEASE alleles.
Vpatient-D(e1,e2)	We have now described three mutations, VARIANT (Scott et al., 1992c), <e1> VARIANT </e1>, and VARIANT totalling 53% of <e2> DISEASE </e2> alleles which together define 28% of MPS-I genotypes.
Vpatient-D(e1,e2)	Allele specific oligonucleotides were used to detect the mutations in a group of 73 DISEASE patients and <e1> VARIANT </e1> was found to account for 15% of all <e2> DISEASE </e2> alleles and VARIANT for 3% of <e2> DISEASE </e2> alleles.
Vpositive-D(e1,e2)	alpha-L-iduronidase mutations (VARIANT and <e1> VARIANT </e1>) associate with a severe <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Allele specific oligonucleotides were used to detect the mutations in a group of 73 <e2> DISEASE </e2> patients and VARIANT was found to account for 15% of all DISEASE alleles and <e1> VARIANT </e1> for 3% of DISEASE alleles.
Vpatient-D(e1,e2)	We have now described three mutations, VARIANT (Scott et al., 1992c), VARIANT, and <e1> VARIANT </e1> totalling 53% of <e2> DISEASE </e2> alleles which together define 28% of MPS-I genotypes.
Vpatient-D(e1,e2)	Allele specific oligonucleotides were used to detect the mutations in a group of 73 DISEASE patients and VARIANT was found to account for 15% of all <e2> DISEASE </e2> alleles and <e1> VARIANT </e1> for 3% of <e2> DISEASE </e2> alleles.
Vpatient-D(e1,e2)	We have now described three mutations, <e1> VARIANT </e1> (Scott et al., 1992c), VARIANT, and VARIANT totalling 53% of <e2> DISEASE </e2> alleles which together define 28% of MPS-I genotypes.
Vpositive-D(e1,e2)	Association of a nonsense mutation (<e1> VARIANT </e1>), the most common mutation in the Ashkenazi Jewish <e2> DISEASE </e2> patients in Israel, with presentation of severe disease.
Vpatient-D(e1,e2)	In conclusion, the <e1> VARIANT </e1> mutation is the most common <e2> DISEASE </e2> mutation in the Ashkenazi Jewish patient population in Israel.
Vpatient-D(e1,e2)	Patients homozygous for the <e1> VARIANT </e1> mutation (n = 16) and patients heterozygous for the VARIANT and <e1> VARIANT </e1> mutations (n = 22) had similarly severe disease, reflected by <e2> DISEASE </e2>, high incidence of DISEASE (37% and 27%, respectively), early age at diagnosis, poor nutritional status, and variable pulmonary function.
Vpatient-D(e1,e2)	Patients homozygous for the <e1> VARIANT </e1> mutation (n = 16) and patients heterozygous for the VARIANT and <e1> VARIANT </e1> mutations (n = 22) had similarly severe disease, reflected by DISEASE, high incidence of <e2> DISEASE </e2> (37% and 27%, respectively), early age at diagnosis, poor nutritional status, and variable pulmonary function.
Vappositive-D(e1,e2)	Only about 30% of the <e2> DISEASE </e2> chromosomes in the Israeli <e2> DISEASE </e2> patient populations carry the major <e2> DISEASE </e2> mutation (<e1> VARIANT </e1>).
Vpatient-D(e1,e2)	Together with the <e1> VARIANT </e1> (23% in this group), VARIANT, VARIANT, and VARIANT mutations, the identification of 92% of <e2> DISEASE </e2> chromosomes of Ashkenazi origin becomes possible.
Vpatient-D(e1,e2)	Patients homozygous for the VARIANT mutation (n = 16) and patients heterozygous for the <e1> VARIANT </e1> and VARIANT mutations (n = 22) had similarly severe disease, reflected by <e2> DISEASE </e2>, high incidence of DISEASE (37% and 27%, respectively), early age at diagnosis, poor nutritional status, and variable pulmonary function.
Vpatient-D(e1,e2)	Patients homozygous for the VARIANT mutation (n = 16) and patients heterozygous for the <e1> VARIANT </e1> and VARIANT mutations (n = 22) had similarly severe disease, reflected by DISEASE, high incidence of <e2> DISEASE </e2> (37% and 27%, respectively), early age at diagnosis, poor nutritional status, and variable pulmonary function.
Vpatient-D(e1,e2)	Together with the VARIANT (23% in this group), <e1> VARIANT </e1>, VARIANT, and VARIANT mutations, the identification of 92% of <e2> DISEASE </e2> chromosomes of Ashkenazi origin becomes possible.
Vpatient-D(e1,e2)	Together with the VARIANT (23% in this group), VARIANT, <e1> VARIANT </e1>, and VARIANT mutations, the identification of 92% of <e2> DISEASE </e2> chromosomes of Ashkenazi origin becomes possible.
Vpatient-D(e1,e2)	Together with the VARIANT (23% in this group), VARIANT, VARIANT, and <e1> VARIANT </e1> mutations, the identification of 92% of <e2> DISEASE </e2> chromosomes of Ashkenazi origin becomes possible.
Vappositive-D(e1,e2)	Incidence and expression of the <e1> VARIANT </e1> mutation of the <e2> DISEASE </e2> (CFTR) gene.
Vpatient-D(e1,e2)	The <e1> VARIANT </e1> mutation was identified in the second nucleotide binding fold of the <e2> DISEASE </e2> (<e2> DISEASE </e2>) gene last year.
Vpatient-D(e1,e2)	<e1> VARIANT </e1>, identified on 216 of nearly 15,000 <e2> DISEASE </e2> chromosomes tested, accounts for 1.5% of all <e2> DISEASE </e2> chromosomes.
Other	We classify <e1> VARIANT </e1> as a " severe " mutation with respect to the pancreas, but can find no correlation between this mutation, in either the homozygous or heterozygous state, and the severity of <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	<e1> VARIANT </e1>, a novel <e2> DISEASE </e2> (<e2> DISEASE </e2>) associated mutation in the first nucleotide binding domain of CFTR, is the second most common <e2> DISEASE </e2> mutation in Portugal.
Other	As it is the case for VARIANT (the most common <e2> DISEASE </e2> mutant), low temperature treatment partially rescues a functional <e1> VARIANT </e1> channel, suggesting that substitution of <e1> VARIANT </e1> does not completely abolish DISEASE function.
Vpatient-D(e1,e2)	Pharmacological strategies previously reported for treatment of <e2> DISEASE </e2> patients with the VARIANT mutation could thus be also effective in <e2> DISEASE </e2> patients bearing the <e1> VARIANT </e1> mutation.
Vpositive-D(e1,e2)	As it is the case for VARIANT (the most common DISEASE mutant), low temperature treatment partially rescues a functional <e1> VARIANT </e1> channel, suggesting that substitution of <e1> VARIANT </e1> does not completely abolish <e2> DISEASE </e2> function.
Vappositive-D(e1,e2)	As it is the case for <e1> VARIANT </e1> (the most common <e2> DISEASE </e2> mutant), low temperature treatment partially rescues a functional VARIANT channel, suggesting that substitution of VARIANT does not completely abolish DISEASE function.
Vpatient-D(e1,e2)	Pharmacological strategies previously reported for treatment of <e2> DISEASE </e2> patients with the <e1> VARIANT </e1> mutation could thus be also effective in <e2> DISEASE </e2> patients bearing the VARIANT mutation.
Other	As it is the case for <e1> VARIANT </e1> (the most common DISEASE mutant), low temperature treatment partially rescues a functional VARIANT channel, suggesting that substitution of VARIANT does not completely abolish <e2> DISEASE </e2> function.
Vpatient-D(e1,e2)	In this study, we present four mutations found in three Japanese patients with the juvenile form of <e2> DISEASE </e2>; three of these mutations were new (<e1> VARIANT </e1>, VARIANT, and VARIANT).
Vpatient-D(e1,e2)	In this study, we present four mutations found in three Japanese patients with the juvenile form of <e2> DISEASE </e2>; three of these mutations were new (VARIANT, <e1> VARIANT </e1>, and VARIANT).
Vpatient-D(e1,e2)	In this study, we present four mutations found in three Japanese patients with the juvenile form of <e2> DISEASE </e2>; three of these mutations were new (VARIANT, VARIANT, and <e1> VARIANT </e1>).
Vpatient-D(e1,e2)	These data suggest that <e2> DISEASE </e2> patients with the <e1> VARIANT </e1> mutation express a functional, but highly unstable, temperature-sensitive bile salt export pump.
Vpatient-D(e1,e2)	Sequence analysis of the coding regions of the <e2> DISEASE </e2> gene revealed germline sequence variants in 68.7% (24 out of 35) of the patients, and four of them presented with undescribed germline alterations: <e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT.
Vpatient-D(e1,e2)	Sequence analysis of the coding regions of the <e2> DISEASE </e2> gene revealed germline sequence variants in 68.7% (24 out of 35) of the patients, and four of them presented with undescribed germline alterations: VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT.
Vpatient-D(e1,e2)	Sequence analysis of the coding regions of the <e2> DISEASE </e2> gene revealed germline sequence variants in 68.7% (24 out of 35) of the patients, and four of them presented with undescribed germline alterations: VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT.
Vpatient-D(e1,e2)	Sequence analysis of the coding regions of the <e2> DISEASE </e2> gene revealed germline sequence variants in 68.7% (24 out of 35) of the patients, and four of them presented with undescribed germline alterations: VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>.
Vpatient-D(e1,e2)	Denaturing high-performance liquid chromatography and direct sequencing of polymerase-chain-reaction products amplified from 10 genetically independent patients with USH2C and 156 other patients with USH2 identified four isoform-specific VLGR1 mutations (<e1> VARIANT </e1>, I2906FS, M2931FS, and T6244X) from three families with <e2> DISEASE </e2>, as well as two sporadic cases.
Vpatient-D(e1,e2)	So far only two recurrent mutations have been identified in <e2> DISEASE </e2> patients by different research groups, i.e., <e1> VARIANT </e1> and VARIANT.
Vpatient-D(e1,e2)	This report demonstrates that rarer mutations other than <e1> VARIANT </e1> and VARIANT can be found in <e2> DISEASE </e2> patients and the need of screening the whole gene in those negative for the commonest mutations.
Vpatient-D(e1,e2)	So far only two recurrent mutations have been identified in <e2> DISEASE </e2> patients by different research groups, i.e., VARIANT and <e1> VARIANT </e1>.
Vpatient-D(e1,e2)	This report demonstrates that rarer mutations other than VARIANT and <e1> VARIANT </e1> can be found in <e2> DISEASE </e2> patients and the need of screening the whole gene in those negative for the commonest mutations.
Vpatient-D(e1,e2)	Genetic analysis of <e1> VARIANT </e1> and VARIANT mutations (USH2A) in patients with <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	The most common mutation in the USH2A gene (Usherin), <e1> VARIANT </e1>, causes both typical <e2> DISEASE </e2> and atypical DISEASE, two DISEASE, characterised by moderate to severe DISEASE and DISEASE (DISEASE).
Vpositive-D(e1,e2)	The most common mutation in the USH2A gene (Usherin), <e1> VARIANT </e1>, causes both typical DISEASE and atypical <e2> DISEASE </e2>, two DISEASE, characterised by moderate to severe DISEASE and DISEASE (DISEASE).
Vpatient-D(e1,e2)	The <e1> VARIANT </e1> mutation was observed in patients with clinical signs of USHII or of atypical <e2> DISEASE </e2>, whereas the VARIANT mutation, regardless of being associated with the <e1> VARIANT </e1> mutation or not, was identified in cases with nonsyndromic DISEASE, as well as in patients with DISEASE associated with a variability of DISEASE.
Vpositive-D(e1,e2)	The most common mutation in the USH2A gene (Usherin), <e1> VARIANT </e1>, causes both typical DISEASE and atypical DISEASE, two <e2> DISEASE </e2>, characterised by moderate to severe DISEASE and DISEASE (DISEASE).
Vpositive-D(e1,e2)	The most common mutation in the USH2A gene (Usherin), <e1> VARIANT </e1>, causes both typical DISEASE and atypical DISEASE, two DISEASE, characterised by moderate to severe <e2> DISEASE </e2> and DISEASE (DISEASE).
Vpositive-D(e1,e2)	The most common mutation in the USH2A gene (Usherin), <e1> VARIANT </e1>, causes both typical DISEASE and atypical DISEASE, two DISEASE, characterised by moderate to severe DISEASE and <e2> DISEASE </e2> (<e2> DISEASE </e2>).
Other	The <e1> VARIANT </e1> mutation was observed in patients with clinical signs of USHII or of atypical DISEASE, whereas the VARIANT mutation, regardless of being associated with the <e1> VARIANT </e1> mutation or not, was identified in cases with nonsyndromic <e2> DISEASE </e2>, as well as in patients with <e2> DISEASE </e2> associated with a variability of DISEASE.
Vpatient-D(e1,e2)	We have investigated the presence of the <e1> VARIANT </e1> and/or the VARIANT mutations in 191 unrelated Spanish patients with different <e2> DISEASE </e2>, or with nonsyndromic DISEASE.
Vpatient-D(e1,e2)	We have investigated the presence of the <e1> VARIANT </e1> and/or the VARIANT mutations in 191 unrelated Spanish patients with different DISEASE, or with nonsyndromic <e2> DISEASE </e2>.
Other	The <e1> VARIANT </e1> mutation was observed in patients with clinical signs of USHII or of atypical DISEASE, whereas the VARIANT mutation, regardless of being associated with the <e1> VARIANT </e1> mutation or not, was identified in cases with nonsyndromic DISEASE, as well as in patients with DISEASE associated with a variability of <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Genetic analysis of VARIANT and <e1> VARIANT </e1> mutations (USH2A) in patients with <e2> DISEASE </e2>.
Other	The VARIANT mutation was observed in patients with clinical signs of USHII or of atypical <e2> DISEASE </e2>, whereas the <e1> VARIANT </e1> mutation, regardless of being associated with the VARIANT mutation or not, was identified in cases with nonsyndromic DISEASE, as well as in patients with DISEASE associated with a variability of DISEASE.
Vpatient-D(e1,e2)	Furthermore, the <e1> VARIANT </e1> mutation in the USH2A gene has been described in 4.5% of patients with nonsyndromic recessive <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	The VARIANT mutation was observed in patients with clinical signs of USHII or of atypical DISEASE, whereas the <e1> VARIANT </e1> mutation, regardless of being associated with the VARIANT mutation or not, was identified in cases with nonsyndromic <e2> DISEASE </e2>, as well as in patients with <e2> DISEASE </e2> associated with a variability of DISEASE.
Vpatient-D(e1,e2)	We have investigated the presence of the VARIANT and/or the <e1> VARIANT </e1> mutations in 191 unrelated Spanish patients with different <e2> DISEASE </e2>, or with nonsyndromic DISEASE.
Vpatient-D(e1,e2)	We have investigated the presence of the VARIANT and/or the <e1> VARIANT </e1> mutations in 191 unrelated Spanish patients with different DISEASE, or with nonsyndromic <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	The VARIANT mutation was observed in patients with clinical signs of USHII or of atypical DISEASE, whereas the <e1> VARIANT </e1> mutation, regardless of being associated with the VARIANT mutation or not, was identified in cases with nonsyndromic DISEASE, as well as in patients with DISEASE associated with a variability of <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	Prevalence of the <e1> VARIANT </e1> mutation in <e2> DISEASE </e2> (DISEASE) in Croatia.
Vpatient-D(e1,e2)	Prevalence of the <e1> VARIANT </e1> mutation in DISEASE (<e2> DISEASE </e2>) in Croatia.
Vpositive-D(e1,e2)	This is the second report of the <e1> VARIANT </e1> mutation in association with <e2> DISEASE </e2>, and supports the existing evidence that the <e1> VARIANT </e1> mutation can result in two quite distinct, yet related, phenotypes.
Vappositive-D(e1,e2)	Here we show that the most common <e2> DISEASE </e2> mutant (<e1> VARIANT </e1>) can form mature, functional chloride channels that reach the cell surface when coexpressed with several other CFTR-processing mutants or with amino fragments of the wild-type CFTR protein.
Vpatient-D(e1,e2)	Expression studies revealed that the VARIANT (VARIANT) change, which was never found alone in a <e2> DISEASE </e2> allele, when found in a double mutant such as [<e1> VARIANT </e1>; VARIANT] ([VARIANT; VARIANT]) and [VARIANT; VARIANT] ([VARIANT; VARIANT]), decreases activity compared to the activity found for the other mutation alone.
Vpatient-D(e1,e2)	Expression studies revealed that the VARIANT (VARIANT) change, which was never found alone in a <e2> DISEASE </e2> allele, when found in a double mutant such as [VARIANT; VARIANT] ([<e1> VARIANT </e1>; VARIANT]) and [VARIANT; VARIANT] ([VARIANT; VARIANT]), decreases activity compared to the activity found for the other mutation alone.
Vpatient-D(e1,e2)	Expression studies revealed that the <e1> VARIANT </e1> (VARIANT) change, which was never found alone in a <e2> DISEASE </e2> allele, when found in a double mutant such as [VARIANT; <e1> VARIANT </e1>] ([VARIANT; VARIANT]) and [VARIANT; <e1> VARIANT </e1>] ([VARIANT; VARIANT]), decreases activity compared to the activity found for the other mutation alone.
Vpatient-D(e1,e2)	Expression studies revealed that the VARIANT (<e1> VARIANT </e1>) change, which was never found alone in a <e2> DISEASE </e2> allele, when found in a double mutant such as [VARIANT; VARIANT] ([VARIANT; <e1> VARIANT </e1>]) and [VARIANT; VARIANT] ([VARIANT; <e1> VARIANT </e1>]), decreases activity compared to the activity found for the other mutation alone.
Vappositive-D(e1,e2)	Other well-established <e2> DISEASE </e2> mutations, namely VARIANT (VARIANT), VARIANT (VARIANT), and <e1> VARIANT </e1> (VARIANT), were also expressed for comparison.
Vpatient-D(e1,e2)	Expression studies revealed that the VARIANT (VARIANT) change, which was never found alone in a <e2> DISEASE </e2> allele, when found in a double mutant such as [VARIANT; VARIANT] ([VARIANT; VARIANT]) and [<e1> VARIANT </e1>; VARIANT] ([VARIANT; VARIANT]), decreases activity compared to the activity found for the other mutation alone.
Vappositive-D(e1,e2)	Other well-established <e2> DISEASE </e2> mutations, namely VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (<e1> VARIANT </e1>), were also expressed for comparison.
Vpatient-D(e1,e2)	Expression studies revealed that the VARIANT (VARIANT) change, which was never found alone in a <e2> DISEASE </e2> allele, when found in a double mutant such as [VARIANT; VARIANT] ([VARIANT; VARIANT]) and [VARIANT; VARIANT] ([<e1> VARIANT </e1>; VARIANT]), decreases activity compared to the activity found for the other mutation alone.
Vappositive-D(e1,e2)	Other well-established <e2> DISEASE </e2> mutations, namely <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), were also expressed for comparison.
Vappositive-D(e1,e2)	Other well-established <e2> DISEASE </e2> mutations, namely VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), and VARIANT (VARIANT), were also expressed for comparison.
Vappositive-D(e1,e2)	Other well-established <e2> DISEASE </e2> mutations, namely VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), and VARIANT (VARIANT), were also expressed for comparison.
Vappositive-D(e1,e2)	Other well-established <e2> DISEASE </e2> mutations, namely VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), and VARIANT (VARIANT), were also expressed for comparison.
Other	The homozygous <e1> VARIANT </e1> mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase results in reduced enzyme activities but not in altered overall cellular sialylation in <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	<e1> VARIANT </e1> mutation in 3 Japanese patients with <e2> DISEASE </e2>.
Vpositive-D(e1,e2)	We describe 3 unrelated Japanese patients with <e2> DISEASE </e2> (<e2> DISEASE </e2>) due to a compound heterozygous <e1> VARIANT </e1> mutation in the MEFV gene.
Vpatient-D(e1,e2)	Our data suggest that it should be recognized that there are more <e2> DISEASE </e2> patients in Japan than previously expected and that the frequency of the <e1> VARIANT </e1> mutation may be significant in Japanese <e2> DISEASE </e2> patients.
Other	Mice bearing different mutations in the murine homolog to CFTR (Cftr) (<e1> VARIANT </e1>, VARIANT, VARIANT, and VARIANT, all backcrossed to the C57BL/6J background) were compared with respect to growth and in their ability to respond to <e2> DISEASE </e2> elicited with Pseudomonas aeruginosa-laden agarose beads.
Vpatient-D(e1,e2)	The inflammatory responses to P. aeruginosa-laden agarose beads were comparable in mice of all four Cftr mutant genotypes with respect to absolute and relative cell counts in bronchoalveolar lavage fluid, and cytokine levels (TNF-alpha, IL-1beta, IL-6, macrophage inflammatory protein-2, and keratinocyte chemoattractant) and eicosanoid levels (PGE2 and LTB4) in epithelial lining fluid: the few small differences observed occurred only between <e2> DISEASE </e2> mice bearing the <e1> VARIANT </e1> mutation and those bearing the knockout mutation VARIANT.
Other	Mice bearing different mutations in the murine homolog to CFTR (Cftr) (VARIANT, <e1> VARIANT </e1>, VARIANT, and VARIANT, all backcrossed to the C57BL/6J background) were compared with respect to growth and in their ability to respond to <e2> DISEASE </e2> elicited with Pseudomonas aeruginosa-laden agarose beads.
Vpatient-D(e1,e2)	The inflammatory responses to P. aeruginosa-laden agarose beads were comparable in mice of all four Cftr mutant genotypes with respect to absolute and relative cell counts in bronchoalveolar lavage fluid, and cytokine levels (TNF-alpha, IL-1beta, IL-6, macrophage inflammatory protein-2, and keratinocyte chemoattractant) and eicosanoid levels (PGE2 and LTB4) in epithelial lining fluid: the few small differences observed occurred only between <e2> DISEASE </e2> mice bearing the VARIANT mutation and those bearing the knockout mutation <e1> VARIANT </e1>.
Other	Mice bearing different mutations in the murine homolog to CFTR (Cftr) (VARIANT, VARIANT, <e1> VARIANT </e1>, and VARIANT, all backcrossed to the C57BL/6J background) were compared with respect to growth and in their ability to respond to <e2> DISEASE </e2> elicited with Pseudomonas aeruginosa-laden agarose beads.
Other	Mice bearing different mutations in the murine homolog to CFTR (Cftr) (VARIANT, VARIANT, VARIANT, and <e1> VARIANT </e1>, all backcrossed to the C57BL/6J background) were compared with respect to growth and in their ability to respond to <e2> DISEASE </e2> elicited with Pseudomonas aeruginosa-laden agarose beads.
Vpatient-D(e1,e2)	Six novel mutations, <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT, VARIANT (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), VARIANT, VARIANT (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), VARIANT, VARIANT (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1>, VARIANT (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, <e1> VARIANT </e1> (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT (<e1> VARIANT </e1>), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT (VARIANT), <e1> VARIANT </e1>, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT (VARIANT), VARIANT, and <e1> VARIANT </e1> (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT (VARIANT), VARIANT, and VARIANT (<e1> VARIANT </e1>), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel <e1> VARIANT </e1> (VARIANT), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	Six novel mutations, VARIANT (VARIANT), VARIANT (VARIANT), VARIANT, VARIANT (VARIANT), VARIANT, and VARIANT (VARIANT), in a total of 14 different mutations, and 13 different polymorphic changes, including the novel VARIANT (<e1> VARIANT </e1>), were identified in a cohort of 10 <e2> DISEASE </e2> patients enrolled in a clinical trial of enzyme-replacement therapy.
Vpatient-D(e1,e2)	The <e1> VARIANT </e1> mutation was observed in five of the seven <e2> DISEASE </e2> patients, suggesting that the mutation is prevalent in Japanese patients.
Vpatient-D(e1,e2)	When combined with the otherwise mild <e1> VARIANT </e1> mutation, the activity is reduced to a level similar to other LIG4 patients who display <e2> DISEASE </e2> and DISEASE.
Vpatient-D(e1,e2)	When combined with the otherwise mild <e1> VARIANT </e1> mutation, the activity is reduced to a level similar to other LIG4 patients who display DISEASE and <e2> DISEASE </e2>.
Vappositive-D(e1,e2)	Analysis of additional mutational changes in <e2> DISEASE </e2> (<e1> VARIANT </e1>, VARIANT and VARIANT) have led to the identification of a nuclear localization signal in DNA ligase IV and sites impacting upon DNA ligase IV adenylation.
Vappositive-D(e1,e2)	Analysis of additional mutational changes in <e2> DISEASE </e2> (VARIANT, <e1> VARIANT </e1> and VARIANT) have led to the identification of a nuclear localization signal in DNA ligase IV and sites impacting upon DNA ligase IV adenylation.
Vappositive-D(e1,e2)	Analysis of additional mutational changes in <e2> DISEASE </e2> (VARIANT, VARIANT and <e1> VARIANT </e1>) have led to the identification of a nuclear localization signal in DNA ligase IV and sites impacting upon DNA ligase IV adenylation.
Vpositive-D(e1,e2)	New mutation (<e1> VARIANT </e1>) of the ATP-7B gene associated with neurologic and neuropsychiatric dominance onset of <e2> DISEASE </e2> in three unrelated Colombian kindred.
Vpositive-D(e1,e2)	A family with <e2> DISEASE </e2> and DISEASE associated with <e1> VARIANT </e1> mutation of the DISEASE gene.
Vpositive-D(e1,e2)	A family with DISEASE and <e2> DISEASE </e2> associated with <e1> VARIANT </e1> mutation of the DISEASE gene.
Vpatient-D(e1,e2)	Three members of an Italian family with DISEASE and multiple <e2> DISEASE </e2> had the <e1> VARIANT </e1> mutation of the DISEASE gene.
Vappositive-D(e1,e2)	A family with DISEASE and DISEASE associated with <e1> VARIANT </e1> mutation of the <e2> DISEASE </e2> gene.
Vappositive-D(e1,e2)	Three members of an Italian family with DISEASE and multiple DISEASE had the <e1> VARIANT </e1> mutation of the <e2> DISEASE </e2> gene.
Vappositive-D(e1,e2)	This indicates that the <e1> VARIANT </e1> mutation of the <e2> DISEASE </e2> gene, lying at the gamma-secretase cleavage site, can be responsible for DISEASE with symptomatic DISEASE.
Vpatient-D(e1,e2)	Three members of an Italian family with <e2> DISEASE </e2> and multiple DISEASE had the <e1> VARIANT </e1> mutation of the DISEASE gene.
Vpositive-D(e1,e2)	This indicates that the <e1> VARIANT </e1> mutation of the DISEASE gene, lying at the gamma-secretase cleavage site, can be responsible for <e2> DISEASE </e2> with symptomatic DISEASE.
Vpositive-D(e1,e2)	This indicates that the <e1> VARIANT </e1> mutation of the DISEASE gene, lying at the gamma-secretase cleavage site, can be responsible for DISEASE with symptomatic <e2> DISEASE </e2>.
Vpatient-D(e1,e2)	The <e2> DISEASE </e2> from the patients with the mutations <e1> VARIANT </e1> and VARIANT showed a reduction of expression of the MLH1-protein, rather than complete loss.
Vpatient-D(e1,e2)	The <e2> DISEASE </e2> from the patients with the mutations VARIANT and <e1> VARIANT </e1> showed a reduction of expression of the MLH1-protein, rather than complete loss.
Vpatient-D(e1,e2)	In the <e2> DISEASE </e2> from the patient with the missense mutation <e1> VARIANT </e1> [VARIANT] a normal expression of the proteins coded by MLH1 and MSH2 was noticed.
Vpatient-D(e1,e2)	In the <e2> DISEASE </e2> from the patient with the missense mutation VARIANT [<e1> VARIANT </e1>] a normal expression of the proteins coded by MLH1 and MSH2 was noticed.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a <e1> VARIANT </e1> (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a <e1> VARIANT </e1> (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (<e1> VARIANT </e1> in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (<e1> VARIANT </e1> in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and <e1> VARIANT </e1> (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and <e1> VARIANT </e1> (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (<e1> VARIANT </e1>), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (<e1> VARIANT </e1>), and 1 case showed double VARIANT (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double <e1> VARIANT </e1> (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double <e1> VARIANT </e1> (VARIANT) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (<e1> VARIANT </e1>) /1834G> A (VARIANT) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (<e1> VARIANT </e1>) /1834G> A (VARIANT) mutations on different alleles.
Vpatient-D(e1,e2)	Among 10 <e2> DISEASE </e2> cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in DISEASE, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (<e1> VARIANT </e1>) mutations on different alleles.
Other	Among 10 DISEASE cases retrospectively collected in Japan, heterozygous missense mutations were found in 9 cases; 4 showed a VARIANT (VARIANT in amino acid change) that has been reported in <e2> DISEASE </e2>, 4 showed novel VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT), and 1 case showed double VARIANT (VARIANT) /1834G> A (<e1> VARIANT </e1>) mutations on different alleles.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vpositive-D(e1,e2)	All the mutations resulted in <e2> DISEASE </e2> defects, and <e1> VARIANT </e1>, VARIANT, VARIANT, and most probably VARIANT, showed reduced binding affinity for BH4.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vpositive-D(e1,e2)	All the mutations resulted in <e2> DISEASE </e2> defects, and VARIANT, <e1> VARIANT </e1>, VARIANT, and most probably VARIANT, showed reduced binding affinity for BH4.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vpositive-D(e1,e2)	All the mutations resulted in <e2> DISEASE </e2> defects, and VARIANT, VARIANT, <e1> VARIANT </e1>, and most probably VARIANT, showed reduced binding affinity for BH4.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), VARIANT (VARIANT), and VARIANT (VARIANT) expressed in E. coli.
Vpositive-D(e1,e2)	All the mutations resulted in <e2> DISEASE </e2> defects, and VARIANT, VARIANT, VARIANT, and most probably <e1> VARIANT </e1>, showed reduced binding affinity for BH4.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), <e1> VARIANT </e1> (VARIANT), and <e1> VARIANT </e1> (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (<e1> VARIANT </e1>), and VARIANT (VARIANT) expressed in E. coli.
Vappositive-D(e1,e2)	With this aim, we optimized the analysis of the kinetic and cofactor binding properties in recombinant human PAH and in seven mild <e2> DISEASE </e2> mutations, i.e., VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), VARIANT (VARIANT), and VARIANT (<e1> VARIANT </e1>) expressed in E. coli.
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: <e1> VARIANT </e1>, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, <e1> VARIANT </e1>, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, <e1> VARIANT </e1> and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and <e1> VARIANT </e1> are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; <e1> VARIANT </e1> and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and <e1> VARIANT </e1> are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1>, VARIANT, VARIANT and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, <e1> VARIANT </e1> and VARIANT are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	Twelve mutations are peculiar to <e2> DISEASE </e2> chromosomes from southern Italy: VARIANT, VARIANT, VARIANT and VARIANT are present in 6.3% of <e2> DISEASE </e2> chromosomes in Campania; VARIANT and VARIANT are present in 9.6% of <e2> DISEASE </e2> chromosomes in Basilicata and VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT, VARIANT and <e1> VARIANT </e1> are frequent in Puglia (19.6% of <e2> DISEASE </e2> alleles).
Vpatient-D(e1,e2)	The <e1> VARIANT </e1> complex allele was present in two <e2> DISEASE </e2> chromosomes, whereas I148T was present in both alleles (as a single mutation) in another <e2> DISEASE </e2> patient and in five <e2> DISEASE </e2> carriers; this could result from crossover events.
